How to buy Edwards Lifesciences stock (EW)

Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $69.38 – an increase of 0.2% over the previous week. Edwards Lifesciences employs 19,800 staff and has a trailing 12-month revenue of around $6.2 billion.

Our top picks for where to buy Edwards Lifesciences stock

Buy Edwards Lifesciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Edwards Lifesciences stock price (NYSE: EW)

Use our graph to track the performance of EW stocks over time.

Edwards Lifesciences shares at a glance

• Key figures

Information last updated 2024-10-24.

Latest market close	$69.38
52-week range	$58.93 - $96.12
50-day moving average more info button	$67.97
200-day moving average more info button	$80.68
Wall St. target price	$75.26
PE ratio more info button	27.8063
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.53

Is it a good time to buy Edwards Lifesciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edwards Lifesciences price performance over time

Historical closes compared with the close of $69.38 from 2024-10-25

1 week (2024-10-22)	0.20%
1 month (2024-09-27)	4.21%
3 months (2024-07-29)	8.85%
6 months (2024-04-29)	-19.28%

1 year (2023-10-27)	12.43%
2 years (2022-10-28)	-2.10%
3 years (2021-10-29)	119.82
5 years (2019-10-29)	79.55

Is Edwards Lifesciences stock undervalued or overvalued?

Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Edwards Lifesciences's P/E ratio

Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Edwards Lifesciences shares trade at around 28x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Edwards Lifesciences's PEG ratio

Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.6903. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Edwards Lifesciences's EBITDA

Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2 billion.

The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure a its profitability.

Edwards Lifesciences financials

Revenue TTM	$6.2 billion
Operating margin TTM	27.22%
Gross profit TTM	$4.3 billion
Return on assets TTM	12.28%
Return on equity TTM	22.02%
Profit margin	23.74%
Book value	$12.35
Market Capitalization more info button	$42.5 billion

TTM: trailing 12 months

Edwards Lifesciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Edwards Lifesciences's total ESG risk score

Total ESG risk: 21.68

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Edwards Lifesciences's environmental score

Environmental score: 4.78/100

Edwards Lifesciences's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Edwards Lifesciences's social score

Social score: 13.43/100

Edwards Lifesciences's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Edwards Lifesciences's governance score

Governance score: 10.96/100

Edwards Lifesciences's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Edwards Lifesciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Edwards Lifesciences Corp was last rated for ESG on: 2019-01-01.

Total ESG score	21.68
Total ESG percentile	24.1
Environmental score	4.78
Environmental score percentile	6
Social score	13.43
Social score percentile	6
Governance score	10.96
Governance score percentile	6
Level of controversy	2

Edwards Lifesciences share dividends

We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.

Have Edwards Lifesciences's shares ever split?

Edwards Lifesciences's shares were split on a 3:1 basis on 31 May 2020 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.

Edwards Lifesciences share price volatility

Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as $58.93 up to $96.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.128. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Edwards Lifesciences overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. .

Frequently asked questions

null
What percentage of Edwards Lifesciences is owned by insiders or institutions?
Currently 0.898% of Edwards Lifesciences shares are held by insiders and 86.881% by institutions. How many people work for Edwards Lifesciences?
Latest data suggests 19,800 work at Edwards Lifesciences. When does the fiscal year end for Edwards Lifesciences?
Edwards Lifesciences's fiscal year ends in December. Where is Edwards Lifesciences based?
Edwards Lifesciences's address is: One Edwards Way, Irvine, CA, United States, 92614 What is Edwards Lifesciences's ISIN number?
Edwards Lifesciences's international securities identification number is: US28176E1082 What is Edwards Lifesciences's CUSIP number?
Edwards Lifesciences's Committee on Uniform Securities Identification Procedures number is: 28176E108